Calidi Biotherapeutics Inc. Featured for Innovative Cancer Treatment Approach

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company, has gained attention for its innovative approach to treating hard-to-treat cancers through systemic genetic medicines. The company's next-generation platform utilizes engineered viruses to deliver genetic therapies directly to tumors, offering a promising avenue for addressing both primary and metastatic cancers. This method not only focuses on oncology but also hints at potential uses in treating autoimmune disorders, suggesting a wide-ranging impact on healthcare. The significance of Calidi's work lies in its potential to contribute to the global fight against cancer, a leading cause of death worldwide, by developing transformative treatment options. For more information, the full press release is available at https://ibn.fm/18sdm.